Skip to Main Content
Frequently Asked Questions
Submit an ETD
Global Search Box
Need Help?
Keyword Search
Participating Institutions
Advanced Search
School Logo
Files
File List
Disserttion kun-yu Teng 110212017.pdf (7.51 MB)
ETD Abstract Container
Abstract Header
Molecular mechanisms underlying microRNA-122 mediated suppression of liver inflammation, fibrosis, and carcinogenesis
Author Info
Teng, Kun-Yu, Teng
ORCID® Identifier
http://orcid.org/0000-0002-1315-3247
Permalink:
http://rave.ohiolink.edu/etdc/view?acc_num=osu1511206344798557
Abstract Details
Year and Degree
2017, Doctor of Philosophy, Ohio State University, Molecular, Cellular and Developmental Biology.
Abstract
MicroRNA-122 (miR-122) is a liver-specific microRNA that maintains liver homeostasis by regulating lipid metabolism, cell differentiation and viral infections in vertebrates. In clinics, hepatocellular carcinoma (HCC) patients with low miR-122 levels are usually associated with poor prognosis, implying miR-122 functions as a tumor suppressor. This notion is supported by the phenotypes of miR-122 genetic knockout (KO) mouse that develops spontaneous hepatitis, steatosis, fibrosis and HCC with age. Although several studies have shown the importance of miR-122 in maintaining liver homeostasis, the mechanisms by which loss of miR-122 contributes to these liver pathological processes remains largely unknown. In the current study, we explored the role of miR-122 in regulating liver inflammation and fibrosis by combining molecular, biochemical, and bioinformatic analysis. We demonstrated that the increased expression of the chemokine CCL2 in the liver is one of the causes of liver inflammation upon deprivation of miR-122. Blocking CCL2 using specific neutralizing antibody (CCL2 nab) ameliorates liver inflammation and tumorigenesis through decreasing the population of CD11b+/Gr1+ cells and their corresponding downstream pathways such as the IL-6-Stat3-cMYC axis and TNF-alpha-NF-kappaB axis. Along with the shrinking tumors in the CCL2 nab treated liver, CCL2 nab also activated natural killer (NK) cells and increased their cytotoxicity toward tumor cells. Besides its robust role in inhibiting liver inflammation and HCC tumors, miR-122 also has a strong anti-fibrosis function. Analyzing database that contained both clinical and expression profiles of liver cirrhosis patients revealed downregulation of miR-122 in the cirrhotic liver tissues compared to normal livers. Ectopic expression of miR-122 in LX-2, an immortalized human hepatic stellate cell (HSC) cell line, reduced cell proliferation and fibrotic gene expressions. Moreover, co-culture of miR-122 expressed HCC cells with miR-122 non-expressing LX-2 cells resulted in miR-122 expression and reduced expression of fibrotic genes, suggesting extracellular miR-122 could be delivered from hepatocytes to HSCs. We next searched hepatic microarray and RNA-seq data in the wild type and miR-122 KO mice to identify miR-122 downstream molecules that promote liver fibrosis. We focused on genes that have been shown to be pro-fibrotic and overexpressed in the human fibrotic livers as well as in the miR-122 KO livers. One such fibrotic gene, B cell lymphoma 2 (BCL2), was found to be upregulated in the HBV- and HCV-infected cirrhotic livers compared to the normal livers (data retrieved from GEO and EMBL-EBI). Besides, BCL2 expression is significantly increased in the mouse livers depleted of miR-122 as demonstrated by microarray, RNA-seq and immunoblot analysis. Venetoclax, an FDA approved BCL2 inhibitor for chronic leukemia lymphoma (CLL), inhibited LX-2 cell proliferation and expression of pro-fibrotic markers, and reduced liver fibrosis in the miR-122 KO mice. Collectively, this study provides a new mechanistic insight on miR-122 mediated suppression of liver inflammation, fibrosis, and HCC. Moreover, our data demonstrated that targeting miR-122 downstream molecules (e.g. CCL2, and BCL2) could be effective in blocking spontaneous liver inflammation, fibrosis and HCCs developed in miR-122 depleted livers.
Committee
Kalpana Ghoshal, Ph.D (Advisor)
samson Jacob, Ph.D (Committee Member)
Jianhua Yu, Ph.D (Committee Member)
David Brigstock, Ph.D (Committee Member)
Pages
161 p.
Subject Headings
Biology
;
Molecular Biology
;
Oncology
Keywords
microRNA-122
;
miR-122
;
C-C chemokine 2
;
CCL2
;
B-cell lymphoma 2
;
BCL2
;
Liver inflammation
;
Liver fibrosis
;
Hepatocellular Carcinoma
;
HCC
Recommended Citations
Refworks
EndNote
RIS
Mendeley
Citations
Teng, Teng, K.-Y. (2017).
Molecular mechanisms underlying microRNA-122 mediated suppression of liver inflammation, fibrosis, and carcinogenesis
[Doctoral dissertation, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1511206344798557
APA Style (7th edition)
Teng, Teng, Kun-Yu.
Molecular mechanisms underlying microRNA-122 mediated suppression of liver inflammation, fibrosis, and carcinogenesis.
2017. Ohio State University, Doctoral dissertation.
OhioLINK Electronic Theses and Dissertations Center
, http://rave.ohiolink.edu/etdc/view?acc_num=osu1511206344798557.
MLA Style (8th edition)
Teng, Teng, Kun-Yu. "Molecular mechanisms underlying microRNA-122 mediated suppression of liver inflammation, fibrosis, and carcinogenesis." Doctoral dissertation, Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1511206344798557
Chicago Manual of Style (17th edition)
Abstract Footer
Document number:
osu1511206344798557
Download Count:
242
Copyright Info
© 2017, some rights reserved.
Molecular mechanisms underlying microRNA-122 mediated suppression of liver inflammation, fibrosis, and carcinogenesis by Kun-Yu Teng Teng is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. Based on a work at etd.ohiolink.edu.
This open access ETD is published by The Ohio State University and OhioLINK.